Variation in Target Attainment of Beta‐Lactam Antibiotic Dosing Between International Pediatric Formularies. Issue 4 (28th February 2021)

• Record Type: Journal Article
• Authors: Gastine, Silke; Hsia, Yingfen; Clements, Michelle; Barker, Charlotte I.S.; Bielicki, Julia; Hartmann, Christine; Sharland, Mike; Standing, Joseph F.
• Is Part Of: Clinical pharmacology & therapeutics. Volume 109:Issue 4(2021)
• Page Start: 958
• Page End: 970
• Publication Date: 2021-02-28
• Subjects: Pharmacology -- Periodicals; Therapeutics -- Periodicals; 615.5
• DOI: 10.1002/cpt.2180
• Languages: English
• ISSNs: 0009-9236

Abstract

Abstract : As antimicrobial susceptibility of common bacterial pathogens decreases, ensuring optimal dosing may preserve the use of older antibiotics in order to limit the spread of resistance to newer agents. Beta‐lactams represent the most widely prescribed antibiotic class, yet most were licensed prior to legislation changes mandating their study in children. As a result, significant heterogeneity persists in the pediatric doses used globally, along with quality of evidence used to inform dosing. This review summarizes dosing recommendations from the major pediatric reference sources and tries to answer the questions: Does beta‐lactam dose heterogeneity matter? Does it impact pharmacodynamic target attainment? For three important severe clinical infections—pneumonia, sepsis, and meningitis—pharmacokinetic models were identified for common for beta‐lactam antibiotics. Real‐world demographics were derived from three multicenter point prevalence surveys. Simulation results were compared with minimum inhibitory concentration distributions to inform appropriateness of recommended doses in targeted and empiric treatment. While cephalosporin dosing regimens are largely adequate for target attainment, they also pose the most risk of neurotoxicity. Our review highlights aminopenicillin, piperacillin, and meropenem doses as potentially requiring review/optimization in order to preserve the use of these agents in future.